Literature DB >> 2975530

Effects of felodipine on natriuresis, atrial natriuretic factor, the renin-angiotensin-aldosterone system, and blood pressure in essential hypertension.

G Cerasola1, S Cottone, M T Mangano, G D'Ignoto, A Pinto, M B Carone.   

Abstract

The aim of this study was to evaluate the short-term and long-term effects of felodipine, a new dihydropiridine calcium antagonist, on arterial blood pressure (BP), the renin-angiotensin-aldosterone system, diuresis, natriuresis, and the atrial natriuretic factor (ANF). In 15 essential hypertensives (WHO class II) BP, venous BP at the posterior tibial vein (VBPTV), diuresis, natriuresis, plasma renin activity (PRA), and both plasma aldosterone and ANF levels were evaluated at the end of a washout period and after two and 24 hours and 30, 90, and 180 days of follow-up with felodipine, 5 mg twice daily. The first dose of felodipine induced a significant decrease in BP, which was associated with increases in both heart rate and VBPTV. An acute diuretic and natriuretic effect, increases in ANF and PRA, and a transient decrease in plasma aldosterone levels were also observed. Throughout the follow-up period, the antihypertensive efficacy remained unchanged, whereas variations in electrolyte balance and hormonal parameters quickly disappeared, except for the increase in PRA, which lasted until the 30th day of therapy. In our study, felodipine showed a great antihypertensive activity during both short-term and long-term treatment. Moreover, the effect of the first dose was characterized by transient increases in circulating ANF and decreases in plasma aldosterone concentrations, which were associated with marked diuresis and natriuresis.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2975530

Source DB:  PubMed          Journal:  Clin Ther        ISSN: 0149-2918            Impact factor:   3.393


  4 in total

1.  Plasma atrial natriuretic peptide levels in essential hypertension after treatment with verapamil.

Authors:  B Kokkas; P Kotridis; M Karamouzis; I Kanonidis; G Sakadamis; G Dadous; S Haritos; P Kyriakoui; P C Papadopoulos; V Mirtsou-Fidani; C L Papadopoulos
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2002 Jan-Mar       Impact factor: 2.441

Review 2.  Felodipine. A review of the pharmacology and therapeutic use of the extended release formulation in cardiovascular disorders.

Authors:  P A Todd; D Faulds
Journal:  Drugs       Date:  1992-08       Impact factor: 9.546

Review 3.  Atrial natriuretic peptide contributes to the antihypertensive action of many drugs.

Authors:  C L Papadopoulos; B A Kokkas
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2003 Jan-Mar       Impact factor: 2.441

Review 4.  Do calcium channel blockers have renal protective effects?

Authors:  G P Reams
Journal:  Drugs Aging       Date:  1994-10       Impact factor: 3.923

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.